Ethical Considerations in Clinical Trials in Asia

Abstract

Clinical trials, by their very nature, are a kind of second choice involving uncertainty from the beginning. The inherent characteristics of clinical trials necessitate ethical considerations. Ethical analysis emphasizes the importance of medical indications, patient preferences, trial quality, and contextual features. Instances of clinical trial misconduct are usually due to insufficient analysis of medical indications, which ignore patient preferences and the way in which investigators assess clinical trial results. These problems are universal concerns. In the context of clinical trials, these are subjective needs in every society. For clinical trials conducted in Asia, ethics must consider the specific needs and benefits of Asian people

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Mason JK, McCall, Smith RA. Law and Medical Ethics. London, Butterworths; 1991.

    Google Scholar 

  2. 2.

    Engelhardt HT, Jr. Bioethics and Secular Humanism: the Search for a Common Morality. London, SCM Press; 1991.

    Google Scholar 

  3. 3.

    Jonsen AR, Siegler M, Winslade WJ. Clinical Ethics. Third edition. New York, NY: McGraw-Hill; 1992.

    Google Scholar 

  4. 4.

    Karlawish JH, Lantos J. Community equipoise and the architecture of clinical research. Camb Q Health Ethics. 1997;6(4):385–396.

    CAS  Article  Google Scholar 

  5. 5.

    Biros MH, Runge JW, Lewis RJ, Doherty C. Emergency medicine and the development of the Food and Drug Administration’s final rule on informed consent and waiver of informed consent in emergency research circumstances. Acad Emerg Med. 1998;5(4):359–368.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  6. 6.

    Varmus H, Satcher D. Ethical complexities of conducting research in developing countries. N Engl J Med. 1997;337(14):1003–1005.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  7. 7.

    Ono S, Kodama Y. Clinical trials and the new good clinical practice guideline in Japan. An economic perspective. Pharmacoecon. 2000;18(2):125–141.

    CAS  Article  Google Scholar 

  8. 8.

    Lynoe N, Sandlund M, Dahlqvist G, Jacobsson L. Informed consent: study of quality of information given to participants in a clinical trial. Br Med J. 1991;303(6803):610–613.

    CAS  Article  Google Scholar 

  9. 9.

    Ijsselmuiden CB, Faden RR. Research and informed consent in Africa—another look. N Engl J Med. 1992;326(12):830–833.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  10. 10.

    Faria SL, Souhami L. Communication with the cancer patient. Information and truth in Brazil. Ann NY Acad Sei. 1997;809:163–171.

    CAS  Article  Google Scholar 

  11. 11.

    Meyza J. Truth-telling, information, and communication with the cancer patients in Poland. Ann NY Acad Sei. 1997;809:468–479.

    CAS  Article  Google Scholar 

  12. 12.

    Verheggen FW, Nieman FH, Reerink E, Kok GJ. Patient satisfaction with clinical trial participation. Int J Qual Health Care. 1998;10(4):319–330.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  13. 13.

    Llewellyn-Thomas HA, McGreal MJ, Thiel EC, Fine S, Erlichman C. Patients’ willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. Soc Sei Med. 1991;32(1):35–42.

    CAS  Article  Google Scholar 

  14. 14.

    Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tan PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli 0157:H7 infections. N Engl J Med. 2000;342(26): 1930–1936.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Pritchard KI. Is tamoxifen effective in prevention of breast cancer? Lancet. 1998;352(9122):80–81.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  16. 16.

    Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, et al. Surrogate end-points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA. 1999;282(8):786–790.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  17. 17.

    LeLorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med. 1997;337(8):536–542.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  18. 18.

    Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355(9209):1064–1069.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  19. 19.

    Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med. 1997;337(12):853–856.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  20. 20.

    Desvarieux M. Questions about a placebo-controlled trial of preventive therapy for tuberculosis in HIV-infected Ugandans. N Engl J Med. 1998;338(12): 841.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  21. 21.

    Perinatal HIV Intervention Research in Developing Countries Workshop Participants. Science, ethics, and the future of research into maternal infant transmission of HIV-1. Lancet. 1999;353(9155):832–835.

    Article  Google Scholar 

  22. 22.

    Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology. A report on principles. Ann IntMed. 1995;123(1):61–70.

    Article  Google Scholar 

  23. 23.

    Bodenheimer T. Health policy report: uneasy alliance—clinical investigators and the pharmaceutical industry. N Engl J Med. 2000;342:1539–1544.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  24. 24.

    Moynihan R, Bero L, Ross-Degnan D, Henry D, Lee K, Watkins J, et al. Coverage by the news media of the benefits and risks of medications. N Engl J Med. 2000,342(22): 1645–1650.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Shretta R, Brugha R, Robb A, Snow RW. Sustain-ability, affordability, and equity of corporate drug donations: the case of Malarone. Lancet. 2000; 355(9216):1718–1720.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  26. 26.

    Hama R. Why Would Drug-Induced Tragedies not End? For the Safety of Drugs. Tokyo, Nihon-Hyo-ronsha; 1996. (in Japanese)

    Google Scholar 

  27. 27.

    Leflar RB. Informed consent and patients’ rights in Japan. Houston Law Rev. 1996;33(1): 1–112.

    CAS  Google Scholar 

  28. 28.

    Tanida N, Yamamoto N, Sashio H, Nakamura Y, Sakagami T, Sawada Y, et al. Influence of truth disclosure on quality of life in cancer patients. Int J Clin Oncol. 1998;3(6):386–394.

    Article  Google Scholar 

  29. 29.

    Younge D, Moreau P, Ezzat A, Gray A. Communicating with the cancer patients in Saudi Arabia. Ann NY Acad Set. 1997;809:309–316.

    CAS  Article  Google Scholar 

  30. 30.

    Monto AS. The disappearance of Reye’s syndrome—A public health triumph. N Engl J Med. 1999;340(18):1423–1424.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  31. 31.

    Johnson GM. Reye’s syndrome. NEngl J Med. 1999; 341(11):846.

    CAS  Google Scholar 

  32. 32.

    Japanese Ministry of Health and Welfare Study Group. The Relationship Between Drugs and Etiology-Unknown Acute Encephalopathy with Serious Sequela. Tokyo, The Ministry of Health and Welfare; 1994. (in Japanese)

    Google Scholar 

  33. 33.

    Japanese Ministry of Health and Welfare. Pharmaceuticals and Medical Devices Safety Information No. 158. January 2000. (in Japanese)

    Google Scholar 

  34. 34.

    Japanese Ministry of Health and Welfare. Pharmaceuticals and Medical Devices Safety Information No. 163. November 2000. (in Japanese)

    Google Scholar 

  35. 35.

    Blanche S. Ethics of placebo-controlled trials of zidovudine to prevent the perinatal transmission of HIV in the Third World. N Engl J Med. 1998; 338(12):837–838.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Barzilai A, Sperling RS, Hyatt AC, Wedgwood JF, Reidenberg BE, Hodes DS. Mother to child transmission of human immunodeficiency virus 1 infection despite zidovudine therapy from 18 weeks of gestation. Pediatr Infect Dis J. 1990;9(12):931–933.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  37. 37.

    Watts DH, Brown ZA, Tartaglione T, Burchett SK, Opheim K, Coombs R, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis. 1991;163(2):226–232.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  38. 38.

    O’Sullivan MJ, Boyer PJ, Scott GB, Parks WP, Weiler S, Blum MR, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol. 1993;168(5):1510–1516.

    PubMed  Article  PubMed Central  Google Scholar 

  39. 39.

    Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173–1180.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  40. 40.

    Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet. 1999;353(9155):773–780.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  41. 41.

    Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R. Efficacy of new, concise schedule for melar-soprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet. 2000;355(9213):1419–1425.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  42. 42.

    Stevenson P. Nepal calls the shots in hepatitis E virus vaccine trial. Lancet. 2000;355(9215):1623.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  43. 43.

    Shalala D. Protecting research subjects—what must be done. N Engl J Med. 2000;343(11):808–810.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  44. 44.

    World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2000;284(23):3043–3045.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Noritoshi Tanida MD, PhD, DTM&H.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tanida, N. Ethical Considerations in Clinical Trials in Asia. Ther Innov Regul Sci 36, 41–49 (2002). https://doi.org/10.1177/009286150203600108

Download citation

Key Words

  • Ethics
  • Clinical trial
  • Asia
  • Placebo
  • Culture